At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Trading 05-20 10:39:48 EDT
5.84
+0.08
+1.39%
High5.86
Low5.64
Vol362.38K
Open5.68
D1 Closing5.76
Amplitude3.82%
Mkt Cap833.15M
Tradable Cap742.21M
Total Shares142.66M
T/O2.09M
T/O Rate0.29%
Tradable Shares127.09M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Aurinia’s LUPKYNIS Deemed Cost-Effective for Lupus
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.